FPA150 Trial Begins Dosing Ovarian, Breast, Endometrial Cancer Patients

FPA150 Trial Begins Dosing Ovarian, Breast, Endometrial Cancer Patients
Five Prime Therapeutics’ ongoing Phase 1 clinical trial has advanced to its Phase 1b expansion portion, in which researchers have begun giving breast, ovarian, and endometrial cancer patients an optimal dose of the company's immune checkpoint inhibitor, FPA150. “We are very pleased with the progress of our FPA150 clinical program,” Helen Collins, senior vice president and chief medical officer at Five Prime, said in a press release. “We have now dosed the first patient in the Phase 1b dose expansion portion of the trial.” “FPA150 specifically targets B7-H4, which is in the same family of checkpoint inhibitors as PD-L1 and is over-expressed in breast and gynecological cancers that are not well served by immunotherapy,” Collins added. This antibody works in two ways. It blocks signals from B7-H4 that prevent immune cells from detecting and eliminating cancer cells, similar to commercially available checkpoint inhibitors, and directly kills B7-H4-positive cells. The Phase 1 trial (NCT03514121) was planned to include two parts. In Phase 1a, researchers included 10 patients with any solid tumor to explore the maximum tolerated dose and recommended dose of FPA150 for further testing. In Phase 1b, researchers will continue studying the selected dose only in breast, ovarian, or endometrial cancer pat
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *